News

In The News ADVI Expert Speaks With Modern Healthcare About What the IRA Means for PBMs
In The News ADVI Discusses Implications of New Drug Price Bill with Bloomberg Law
In The News ADVI’s Lindsay Bealor Greenleaf told BioWorld that whether the launch interchangeable insulin biosimilars will result in lower costs for patients will be decided by PBMs.
In The News ADVI’s Lindsay Bealor Greenleaf spoke to BioWorld about the latest congressional scrutiny around prescription drug list price increases and the overlooked role played by pharmacy benefit managers.
In The News ADVI’s Lindsay Bealor Greenleaf spoke to AISHealth about CMS’ recent proposal to rein in pharmacy price concessions imposed by pharmacy benefit managers
In The News ADVI’s Lindsay Bealor Greenleaf spoke to AIS Health about a new report on PBMs & their ability to manufacture profits at the expense of patients.
In The News The House passed the Build Back Better reconciliation bill on Friday, which includes authorization for the government to negotiate lower drug prices. ADVI Health’s Lindsay Bealor Greenleaf shared insights on the measure with Pharmacy Times
In The News ADVI’s Lindsay Bealor Greenleaf shared her insights with AISHealth on a majorly overlooked aspect of the Build Back Better Act
In The News ADVI’s Lindsay Bealor Greenleaf talked to Pharmacy Times about the role of the federal government in drug pricing & how the Build Back Better Act would impact it moving forward